2020 |
Anna Magg |
Does the SSCP bring the desired transparency for the European patients and the general public - Critical Assessment from an industry perspective |
|
|
2020 |
Dr. Sonja Matt |
Regulatory considerations for the development of next generation antibody-based therapeutics: Historical overview and quality requirements in the EU *** |
|
|
2020 |
Dr. Daniela Matthey-Inführ |
The new guideline ICH Q12 and its application to the production transfer of European approved and approvable medicinal products to a new manufacturing site - Does it provide any new benefits for the regulatory strategy? *** |
|
|
2020 |
Monique Mendel-Ott |
The impact of changing legislation on the development, marketing authorisation and commercialization of medicinal products *** |
|
|
2020 |
Mariam Motamen |
Simplification Instead of Complication: A Critical Assessment of Pharmacovigilance Legislation from an Industry Perspective *** |
|
|
2020 |
Dr. Christina Nöcker |
Implementation of TPO IV in Switzerland - implications for regulatory strategies and comparison with the European legislation *** |
|
|
2020 |
Kateryna Popova |
Normative Documentation in CIS region. Challenges for an EU Marketing Authorization Holder *** |
|
|
2020 |
Dr. Inga Reimer |
ASMF Worksharing Procedure - Challenges and Advantages |
|
|
2020 |
Dr. Jasmin Rickmeyer |
Impact of the Covid-19 pandemic on the management and conduct of ongoing clinical trials with medicinal products *** |
|
|
2020 |
Dr. Ann-Kathrin Ridder |
Interface Pharmacovigilance and Regulatory Affairs; Establishment of a continous IT-process for implemention of pharmacovigilance procedures *** |
|
|
2020 |
Dr. Ekaterine Schäfer |
Evaluation of Non-clinical Requirements for Medicinal Products containing Monoclonal Antibodies as an Active Substance based on review of EPARS during last 10 years (2010-2019) *** |
|
|
2020 |
Dr. Kendra Schafti |
New challenges in biosimilar development in the context of current regulatory guidance *** |
|
|
2020 |
Dr. Sabine Schürmann |
The labelling of excipients relevant to food allergies or food intolerances in the product information for medicinal products for human use in the EU *** |
|
|
2020 |
PD Dr. Ganna Staal (geb. Kalayda) |
History of platinum-based drugs from a regulatory perspective *** |
|
|
2020 |
Olguta Stanescu |
Considerations on regulatory requirements for registration of drug-device combination products in Canada and the European Union *** |
|
|
2020 |
Kathrin Sugg |
Assessment of the Quality Part of a Finished Product Dossier of old products - Typical gaps, possible root causes, consequences of gaps *** |
|
|
2020 |
Anna von Medem |
Vor- und Nachteile der europäischen Implementierung über SPOR anhand des Anwendungsbeispiels der eSubmission *** |
|
|
2020 |
Dr. Felicitas Wendling |
Regulatory Considerations regarding Multilingual Labelling in the EU |
|
|
2020 |
Dr. Hilke Zander |
Regulatory requirements for histology independent indications in oncology *** |
|
|
2019 |
Kristina Baitinger |
Application for Marketing Authorisation for a Generic Medicinal Product in Germany and Canada - Comparative presentation of content in Module 3 considering the country specific Regulatory Requirements |
|
|